trending Market Intelligence /marketintelligence/en/news-insights/trending/tD97JAgNBg2pUCVOZibLRA2 content esgSubNav
In This List

EU agency accepts AstraZeneca application for Tagrisso in 1st-line lung cancer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


EU agency accepts AstraZeneca application for Tagrisso in 1st-line lung cancer

AstraZeneca PLC said the European Medicines Agency accepted its submission for Tagrisso as a first-line treatment for a certain type of lung cancer.

The company submitted a variation to its marketing authorization application to use Tagrisso, or osimertinib, to treat adults with locally advanced or metastatic non-small cell lung cancer, or NSCLC, whose tumors have epidermal growth factor receptor, or EGFR, mutations.

The submission is based on data from the phase 3 Flaura trial, under which Tagrisso significantly improved progression-free survival compared to erlotinib or gefitinib in previously-untreated patients with locally-advanced or metastatic EGFRm NSCLC.

Recently, AstraZeneca sought Japan's approval to use Tagrisso as first-line treatment of patients in inoperable or recurrent EGFR-mutated NSCLC.